Facebook
X
LinkedIn
ForwardMomentum in MDS: Making Progress and Shaping a Better Future
The MDSF ASH 2025 Symposium will focus on several topics within the interests of the general hematologic society in general, and the MDS community in particular, as well as the general public, including patients and their caregivers. A special emphasis will be given to topics relevant especially in 2025.
Target Audience
This activity is designed for an audience of nurses, pharmacists, physicians, and physician associates.
Learning Objectives
- Identify and apply updated international guidelines for the diagnosis and treatment of Myelodysplastic Syndromes (MDS), enhancing global clinical practice.
- Evaluate the current and future role of morphology in MDS, and distinguish when traditional techniques are necessary versus when modern technologies may provide suitable alternatives.
- Analyze emerging evidence on germline predisposition in MDS and determine appropriate conditions for proactive versus conservative management strategies.
- Explain the general process of drug development, with a focus on MDS, and interpret clinical trial data to inform real-world treatment decisions.
- Integrate scientific findings with patient perspectives by discussing real-life challenges, thereby enhancing patient-centered care in MDS management.
Commercial Support
This activity is supported from an independent medical education grant from XX.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to [email protected] with your information with "Opt Out" in the subject line.
Rafael Bejar, MD, PhD
Carmelo Gurnari, MD PhD
Peggy Ann Torney
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and MDS. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 3 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 3 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacists
AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 3 contact hours.
Nursing
Credit being awarded: 3 ANCC contact hours
Physician Associates
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 3 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Available Credit
- 3.00 AAPA Category 1 CME
- 3.00 ACPE Pharmacist
- 3.00 AMA PRA Category 1 Credit™
- 3.00 ANCC
- 3.00 Attendance